Cephalotaxine

CAS No. 24316-19-6

Cephalotaxine( (-)-Cephalotaxine, Cephalotaxine )

Catalog No. M17450 CAS No. 24316-19-6

Cephalotaxine is an antiviral and an antitumor agent.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 49 In Stock
10MG 69 In Stock
25MG 123 In Stock
50MG 176 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Cephalotaxine
  • Note
    Research use only, not for human use.
  • Brief Description
    Cephalotaxine is an antiviral and an antitumor agent.
  • Description
    Cephalotaxine is an antiviral and antitumor agent.
  • In Vitro
    Cephalotaxine inhibits Zika infection by impeding viral replication and stability.
  • In Vivo
    ——
  • Synonyms
    (-)-Cephalotaxine, Cephalotaxine
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    Antiviral
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    24316-19-6
  • Formula Weight
    315.37
  • Molecular Formula
    C18H21NO4
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : ≥ 100 mg/mL; 317.10 mM
  • SMILES
    O[C@H]1[C@@H]2[C@@]3(N(CCc4c2cc2OCOc2c4)CCC3)C=C1OC
  • Chemical Name
    (11bS,12S,14aR)-13-methoxy-2,3,5,6,11b,12-hexahydro-1H-[1,3]dioxolo[4',5':4,5]benzo[1,2-d]cyclopenta[b]pyrrolo[1,2-a]azepin-12-ol

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. M A Sells, et al. J Virol. 1988 Aug; 62(8): 2836–2844.
molnova catalog
related products
  • AG-825

    AG-825(Tyrphostin C15) is a selective and competitive ErbB2 inhibitor that inhibits tyrosine phosphorylation with an IC50 value of 0.35 μM.AG-825 (Tyrphostin C15) inhibits HER2 and shows anticancer activity in a mouse xenograft model of breast cancer.

  • Tyrphostin AG 112

    Tyrphostin AG 112 is an inhibitor of EGFR phosphorylation.

  • Mutated EGFR-IN-1

    Mutated EGFR-IN-1 is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant, and T790M resistance mutant.